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Introduction
Colorectal carcinoma (CRC) is the third most frequent malignancy 
and the second leading cause of cancer-related deaths worldwide 
(1, 2). In 2018, more than 1.8 million patients were newly diagnosed 
with CRC, and despite improved 5-year survival rates, the estimat-
ed number of CRC-related deaths accumulated to 881,000 (3–6). 
Successful immunotherapeutic interventions in other solid cancers, 
such as melanoma and lung carcinoma, have exploited the tumor 
microenvironment, which contains high numbers of immune cells, 
such as T cells, NK cells, and antigen-presenting cells (7, 8). The 
majority of CRCs, however, lack prominent immune infiltrates and 
only approximately 4% of all patients with CRC respond to immu-
notherapies (2, 9). Immunogenic CRCs are characterized by mis-
match repair deficiency and high microsatellite instability resulting 
in a high tumor mutation rate (2). In contrast, the majority of CRC 
tumors exhibit low immunogenicity and evade eradication by cir-
culating T cells and NK cells via expression of immunosuppressive 
modulators such as TGF-β, recruitment of Tregs, and promotion of 
myeloid-derived suppressor cells (10). This absence of antitumor 
immune cell recruitment is the main hurdle for successful immu-
notherapy and generates a high need for effective immune modu-
lators to render colorectal tumors more immunogenic (2).
Protein tyrosine phosphatase nonreceptor type 2 (PTPN2) 
has recently been suggested as a possible target for tumor thera-
py (11–13). PTPN2 is a ubiquitously expressed antiinflammatory 
protein known to regulate proinflammatory signaling pathways 
by direct dephosphorylation of several JAKs, STAT family mem-
bers, and others (14–17). Total body deficiency of PTPN2 in mice 
causes severe systemic inflammation and death within 3–5 weeks 
of birth. Therefore, mice with cell type–specific PTPN2 deletions 
have been developed (18).
We have recently shown that loss of PTPN2 in myeloid cells 
and intestinal epithelial cells reduce tumor load and promote 
immune responses against tumors in a model of colitis-associ-
ated colon cancer by increasing IL-1β production and elevating 
immunogenicity of the tumor (19). Tumor cell–specific and T 
cell–specific PTPN2 deletion has been reported to reduce tumor 
load in s.c. tumor models using melanoma and CRC cell lines as 
well as in mammary tumor models (11–13). In humans, reduced 
PTPN2 expression correlated with a better treatment response 
in T cell acute lymphoblastic leukemia in children (20). Howev-
er, the molecular role of PTPN2 in T cells in the context of diffi-
cult-to-treat solid tumors has not been studied in depth, and little 
is known about its role in human CRC.
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PTPN2+ infiltrating immune cells at this stage. Stage IV tumors 
emerge upon significant changes in the expression of various 
genes that not only enables tumor cell migration and metastasis 
formation, but also evasion of detection by the immune system. 
These changes not only affect gene expression in tumor cells, but 
likely also affect the activity and function of PTPN2, not only in the 
tumor but also in surrounding immune cells, specifically T cells. 
Thus, it is not surprising that expression of the analyzed factors 
STAT1, CXCL11, and GZMA, which are associated with immune 
cell infiltration and activation, shows an opposite correlation with 
PTPN2 in stage IV tumors.
Finally, we explored PTPN2 protein expression and localiza-
tion of checkpoint molecules in primary CRC, liver metastasis, 
and melanoma. For primary CRC, we found that high PTPN2 
expression in CRC tumor tissues correlated with low checkpoint 
molecule expression, similar to liver metastasis, in which low lev-
els of PTPN2 expression within tumor tissues were associated 
with strong PD-1 and CTLA4 staining (Figure 1F and Supplemen-
tal Figure 1, A and B; supplemental material available online with 
this article; https://doi.org/10.1172/JCI140281DS1). On the con-
trary, we observed high levels of PTPN2 expression, which slightly 
positively correlated with expression of PD-1 in melanoma, show-
ing that highly immunogenic tumors have a different PD-1 asso-
ciation with PTPN2 (Supplemental Figure 1A). Taken together, 
these patient studies demonstrate an increase in PTPN2 levels in 
immune cells in progressing CRC tumors and reveal that PTPN2 
could be a mediator of decreased CRC immunogenicity.
Loss of PTPN2 in T cells reduces tumor burden in the AOM/
DSS tumor model. Our results from patients suggest a crucial 
role of PTPN2 in immune cells during CRC development. To 
confirm this hypothesis, we investigated the role of PTPN2 in T 
cells in CRC mouse models. In a first approach, we applied the 
azoxymethane/dextran sodium sulfate (AOM/DSS) CRC model 
in Ptpn2fl/fl Cd4Cre+/– (referred to as ΔT in the figures) mice lack-
ing PTPN2 specifically in both CD4+ and CD8+ T cells (22, 23). 
Ptpn2fl/fl (WT) littermates not carrying the Cre construct were 
used as controls (Figure 2A).
In AOM/DSS-treated WT mice, we observed prominent 
tumor growth in the distal part of the colon when compared with 
Ptpn2fl/fl Cd4Cre+/– littermate controls, whereas the controls showed 
no visual differences between genotypes (Figure 2B). The size and 
number of tumors were significantly reduced in Ptpn2fl/fl Cd4Cre+/– 
mice compared with their WT littermate controls (Figure 2C). 
H&E staining of colon sections showed highly increased immune 
cell infiltration into tumor tissues in Ptpn2fl/fl Cd4Cre+/– mice com-
pared with WT littermates (Figure 2D), and IHC staining for CD3 
revealed augmented accumulation of T cells into the tumors of 
these mice (Figure 2E).
RNA-Seq of colon tissues from water-treated (healthy tis-
sue) and AOM/DSS-treated (nontumor and tumor tissue) WT 
and Ptpn2fl/fl Cd4Cre+/– mice revealed that AOM/DSS treatment in 
Ptpn2fl/fl Cd4Cre+/– mice showed the highest change in the expres-
sion of genes involved in CD8+ T cell signaling, cytotoxicity, and 
infiltration, including STAT1, IFN-γ, granzyme family, checkpoint 
molecule, and chemokine genes (Figure 2F and Supplemental 
Figure 2A). We performed quantitative PCR (qPCR) to confirm 
the significant changes in chemokine expression observed in the 
Here, we demonstrate that increased PTPN2 expression in 
human CRC tissue, and especially in infiltrating lymphocytes, 
correlates with reduced levels of T cell activity and cytotoxicity. 
Further, we show that PTPN2 deletion in T cells lowers tumor load 
in orthotopic and heterotopic CRC and melanoma mouse models 
and enhances T cell activity, infiltration, and cytotoxicity, thus 
rendering tumors more immunogenic. Finally, PTPN2 deletion in 
T cells potentiates the efficacy of anti–PD-1 treatment, resulting in 
more effective tumor clearance and immune memory formation. 
These data indicate that PTPN2 may be a very promising stand-
alone or combination therapy target in CRC.
Results
PTPN2 expression is increased in patients with CRC. To investigate 
the importance of PTPN2 in the pathogenesis of human CRC, we 
first analyzed PTPN2 protein levels in colonic nontumor versus 
tumor tissues from patients with CRC using IHC. Although PTPN2 
expression in nontumor tissues was moderate, we observed sig-
nificantly enhanced levels of PTPN2 in CRC tumor tissues at all 
stages (Figure 1A). We found that PTPN2 phosphatase activity 
was increased in CRC tumor tissues compared with nontumor tis-
sues from the same patient (Figure 1B). Consistent with enhanced 
PTPN2 activity, the levels of phosphorylated STAT1 (p-STAT1), 
a direct PTPN2 target, were low and inversely correlated with 
PTPN2 protein expression (Figure 1C).
PTPN2 was mainly expressed in tumor cells, but interesting-
ly, in stages I–III, we observed increasing numbers of CD3+ cells, 
which were positive for PTPN2, whereas PTPN2 expression levels 
in the cancer cells did not change across the tumor stages. Stage 
IV tissue, however, showed lower numbers of PTPN2+ infiltrating 
CD3+ cells (Figure 1D), probably because of the overall reduced 
levels of CD3+ cells. Since PTPN2 and p-STAT1 are suggested to 
modulate T cell recruitment and activity (11, 21), we investigat-
ed whether PTPN2 expression correlates with T cell–associated 
genes, such as STAT1, CXCL11, and granzyme A (GZMA), which 
are required for T cell activity, recruitment, and cytotoxicity, 
respectively. We observed an inverse correlation in stages I–III for 
the ratios of STAT1/PTPN2, CXCL11/PTPN2, and GZMA/PTPN2 
(Figure 1E). Stage IV tumors, however, showed a direct correlation 
for all 3 genes (Figure 1E), indicating a change in immune activi-
ty in metastatic tumors and highlighting the observation of fewer 
Figure 1. Enhanced PTPN2 expression in human CRC. (A) Representative 
images and quantification of PTPN2 IHC staining in nontumor (Non T) 
and stage I–IV tumor tissue. Scale bars: 50 μm. P values were determined 
by 1-way ANOVA with Tukey’s multiple-comparison test. Data represent 
the mean ± SD. (B) PTPN2 phosphatase activity in nontumor and tumor 
tissue (n = 10 samples per condition). P values were determined by 2-tailed 
Mann-Whitney U test. (C) Correlation between PTPN2 and p-STAT1 protein 
quantification and (D) immunofluorescence costaining for CD3 (AF594, 
green), PTPN2 (AF647, red), and DAPI. Original magnification, 40×; zoom 
factor, 3.0. P and R2 values in C were determined by linear regression 
analysis. (E) Correlations between PTPN2 and STAT1 and between CXCL11 
and GZMA mRNA expression. P and R2 values were determined by linear 
regression analysis. (F) Representative images of IHC and correlations 
between PTPN2 and the checkpoint molecule PD-1 in primary CRC. Scale 
bars: 100 μm. P values and R2 values were determined by linear regression 
analysis. HPF, high-power field.
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Supplemental Figure 3, A–C). Similar to CD4+ T cells, PTPN2-defi-
cient CD8+ T cells expressed more IFN-γ than did those from WT 
mice, but the frequencies did not differ between healthy tissue, 
inflamed (nontumor) tissue, and tumor tissue (Figure 3F).
In WT mice, the frequency of CD4+PD-1+, but not CD8+PD-1+, 
T cells was significantly increased in nontumor and tumor tissue 
when compared with frequencies in healthy tissue (Figure 3F). In 
contrast, the frequency of CD4+PD-1+ cells did not differ between 
tissues from water- and AOM/DSS-treated Ptpn2fl/fl Cd4Cre+/– mice 
and was overall significantly lower than that in WT littermates 
(Figure 3F). Nevertheless, we observed a clear increase in PD-1 
expression on Ptpn2fl/fl Cd4Cre+/– CD8+ T cells in inflamed nontumor 
colon and tumor tissues compared with healthy colon tissues, but 
its expression was still lower than in WT mice (Figure 3F).
PTPN2 T cell deficiency reduces tumor burden independently of 
inflammation. We next assessed the tumor burden in inflamma-
tion-independent models of CRC, namely the orthotopic MC38 
cell cecal injection model and the genetic APCmin mouse model.
Remarkably, using the cecal injection model, approximate-
ly 60% of Ptpn2fl/fl Cd4Cre+/– mice completely cleared the tumors, 
and the remaining tumors were relatively small, whereas WT mice 
showed a failure of tumor control (Figure 4, A and B). IHC and flow 
cytometric analyses of CD8+ T cells showed enhanced infiltration 
of CD8+ T cells into tumors in Ptpn2fl/fl Cd4Cre+/– mice compared 
with WT littermate controls (Figure 4C). Again, we observed 
increased expression of chemokines in tumors from Ptpn2fl/fl 
Cd4Cre+/– mice, which further supports the idea of increased CD8+ 
T cells infiltration into the tumor as a mechanism for reduced 
tumor burden (Supplemental Figure 4A).
We observed a comparable increase in systemic CD8+ T cell 
activation upon loss of PTPN2 in both the AOM/DSS and cecal 
injection tumor models, suggesting that initial inflammation was 
not required for T cell activation or tumor clearance (Figure 4D). 
Furthermore, we found similar expression levels of cytotoxicity 
markers in both tumor models, including increased granzyme B 
and IFN-γ expression in tumor tissues from Ptpn2fl/fl Cd4Cre+/– mice 
compared with expression in WT littermate controls (Figure 4E). 
Notably, in the cecal injection model, PD-1 expression on CD8+ 
T cells was significantly increased in Ptpn2fl/fl Cd4Cre+/– mice com-
pared with expression in WT control mice (Figure 4E).
In the genetic APCmin model of CRC, Ptpn2fl/fl Cd4Cre+/–APC­
min mice showed an extensive reduction of tumor burden in the 
small intestine when compared with Ptpn2fl/fl APCmin littermates 
(Figure 4F), and Ptpn2fl/fl Cd4Cre+/–APCmin mice had healthy 
spleens, whereas Ptpn2fl/fl APCmin mice had spleens that were sig-
nificantly heavier (Figure 4F) and an unhealthy, pale color.
Finally, to validate whether PTPN2 deletion in T cells exerts 
not only local effects in the colon, but is also relevant for systemic 
tumors, we next applied the s.c. injection model using MC38 CRC 
and B16 melanoma cells. Consistent with our findings with in situ 
tumors, we observed slower tumor growth and reduced size and 
weight in Ptpn2fl/fl Cd4Cre+/– mice compared with WT mice, regard-
less of the cancer cell type, i.e., MC38 or B16 (Figure 5, A and B, 
and Supplemental Figure 5, A and B).
PTPN2­deficient CD8+ T cells are the key mediators of antitumor 
efficacy. Given the prominent changes in CD8+ T cells revealed in 
all our data, CD8+ T cell depletion in the MC38 s.c. injection mod-
RNA-Seq analyses (Supplemental Figure 2B). Similar to the data 
obtained by RNA-Seq, we found that CXCL9, CXL11, CXCR3, and 
CXCR5 chemokines were significantly upregulated in tumor tis-
sue from Ptpn2fl/fl Cd4Cre+/– mice compared with expression levels 
in tissue from their littermate controls. Collectively, these findings 
indicate that PTPN2 deletion in T cells led to changes in the cyto-
toxic T cell compartment in the inflammation-dependent AOM/
DSS CRC model.
PTPN2 regulates the expression, activation, and tumor infiltration 
of CD8+ cytotoxic T cells. To further investigate the alterations in T 
cell function/activation caused by PTPN2 deletion, we examined 
CD4+ and CD8+ T cells in detail. IHC and flow cytometric analyses 
of CD4+ T cells in healthy colon, inflamed nontumor, and tumor 
tissues did not reveal significant differences in the frequencies of 
CD4+ T cells between Ptpn2fl/fl Cd4Cre+/– and WT mice (Figure 3A). 
Nevertheless, effector/memory CD4+ T cells were increased in the 
spleen and mesenteric lymph nodes (mLNs) of Ptpn2fl/fl Cd4Cre+/– 
mice, independent of the treatment (Figure 3B). However, no 
signs of microscopic inflammation or morphologic changes were 
detectable in the colon of unchallenged Ptpn2fl/fl Cd4Cre+/– mice. 
Flow cytometry showed a clear increase in Th1 (CD4+IFN-γ+) cells, 
while Th2 cells (CD4+IL-4+), Th17 cells (CD4+IL-17+), and Tregs 
(CD4+FoxP3+) showed no significant changes between Ptpn2fl/fl 
Cd4Cre+/– mice and their WT littermate controls (Figure 3C and 
Supplemental Figure 3A).
Of note, we detected increased infiltration and frequency of 
CD8+ T cells in inflamed nontumor and tumor tissues from Ptpn2fl/fl 
Cd4Cre+/– mice by IHC and flow cytometry (Figure 3D). This increase 
in CD8+ T cell infiltration is well in line with the upregulation of 
chemokines and chemokine receptors observed in the tumor tis-
sue. A predominant fraction of CD8+ T cells was activated effector/
memory (CD8+CD44+CD62L–) T cells in the spleen and mLNs of 
both water-treated control and AOM/DSS-treated mice (Figure 3E). 
Although comparable frequencies of PTPN2-deficient CD8+ T cells 
were activated in water- and AOM/DSS-treated mice, the frequen-
cy of granzyme B–positive cells was clearly increased specifically in 
tumor tissue, an effect completely absent in WT mice (Figure 3F and 
Figure 2. PTPN2 deletion in T cells leads to reduced tumor burden in coli-
tis-associated tumors. Tumors were induced in Ptpn2fl/fl Cd4Cre+/– mice (ΔT) 
(n = 10) and littermate control Ptpn2fl/fl mice (WT) (n = 12) using the AOM/
DSS model (n = 2 independent experiments). Mixed WT controls (Ptpn2fl/fl  
Cd4Cre– and Ptpn2fl/fl Cd11cCre–) were used in this experiment. (A) Schematic 
overview of the experimental procedure. (B) Representative colonoscopy 
images from untreated and AOM/DSS-treated mice. (C) Quantification of 
the total number of tumors, stratified by tumor size. P values were deter-
mined by 2-tailed Mann-Whitney U test. (D) H&E staining of tumor tissue 
from Ptpn2fl/fl Cd4Cre+/– and Ptpn2fl/fl mice. Scale bars: 100 μm. (E) Represen-
tative images and quantification of CD3 staining in Ptpn2fl/fl Cd4Cre+/–  and 
WT tumor tissue. RNA-Seq was performed on untreated, inflamed nontu-
mor, and inflamed tumor tissue from WT and Ptpn2fl/fl Cd4Cre+/– mice (n = 4 
mice each). Scale bars: 50 μm. P values were determined by 1-way ANOVA 
with Tukey’s multiple-comparison test. (F) Heatmap of mRNA expression 
levels of T cell–related genes from WT inflamed nontumor tissue (WT 
non-T), WT inflamed tumor tissue (WT T), Ptpn2fl/fl Cd4Cre+/– untreated 
tissue (ΔT), Ptpn2fl/fl Cd4Cre+/– inflamed nontumor tissue (ΔT non-T), and 
Ptpn2fl/fl Cd4Cre+/– inflamed tumor tissue (ΔT T) normalized to the expression 
levels in colon tissue from water-treated WT mice. False sign rate, *P < 
0.01, **P < 0.001, and ***P < 0.0001. Data represent the mean ± SD.
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el abrogated the protective effect of PTPN2 deficiency, resulting 
in similar tumor growth and terminal weight in Ptpn2fl/fl Cd4Cre+/– 
mice and WT littermates (Figure 5, C and D).
IHC staining and flow cytometric analysis revealed highly 
increased infiltration of PTPN2-deficient CD8+ T cells into the 
tumor in isotype-treated control mice, whereas CD8+ T cells were 
successfully depleted in both mouse lines (Figure 5E). Of note, we 
observed an inverse correlation between tumor weight and CD8+ 
T cell frequency in the tumor tissues from Ptpn2fl/fl Cd4Cre+/– mice, 
while in WT mice, such a correlation was not detectable (Figure 5F).
In contrast to the drastic effects of CD8 depletion, CD4+ T 
cell depletion did not affect the tumor suppression capacity in 
Ptpn2fl/fl Cd4Cre+/– mice. Although tumor growth was slightly sup-
pressed upon CD4+ T cell depletion in WT mice (Figure 5, G and 
H, and Supplemental Figure 6A), which might have resulted from 
the depletion of Tregs, we did not further investigate this in this 
study. Flow cytometric analysis revealed complete CD4+ T cell 
depletion in the spleen and a reduction of approximately 80% in 
tumor tissue (Supplemental Figure 6B). The expression of gran-
zyme B and IFN-γ was significantly higher in Ptpn2fl/fl Cd4Cre+/– 
mice when compared with expression in WT mice with or with-
out CD4 depletion (Supplemental Figure 6C). Thus, CD4+ T cells 
were not required for tumor suppression in Ptpn2fl/fl Cd4Cre+/– mice.
To further investigate the antitumor potential of PTPN2- 
deficient CD8+ T cells, we injected MC38 cells into Rag2-defi-
cient mice, followed by adoptive transfer of either WT or PTPN2- 
deficient CD8+ T cells on day 6 (Figure 6A). Remarkably, tumor 
growth was significantly slower in mice that received CD8+ T cells 
from Ptpn2fl/fl Cd4Cre+/– mice, further demonstrating the prominent 
role of CD8+ T cells in reducing tumor burden in Ptpn2fl/fl Cd4Cre+/– 
mice (Figure 6B).
We confirmed the increased antitumor capacity of PTPN2- 
deficient T cells in an in vitro killing assay, in which we incubat-
ed MC38 and MC38-OVA–expressing cells with Ptpn2fl/fl OT-I or 
Ptpn2fl/fl Cd4Cre+/–OT-I cells. PTPN2-deficient OT-I cells were more 
efficient at antigen-specific tumor killing when compared with 
PTPN2-proficient OT-I cells (Figure 6C).
PTPN2 deletion in DCs leads to reduced tumor burden in both 
AOM/DSS and orthotopic injection models. In light of our findings 
in mice lacking PTPN2 in T cells, we investigated whether dele-
tion of PTPN2 in antigen-presenting cells, specifically DCs, also 
affects tumor development in our CRC models. Of note, our pre-
vious work showed a significant tumor reduction in mice lacking 
PTPN2 in myeloid cells (19), but the effect of PTPN2 depletion in 
DCs on CRC development is still unknown.
To this aim, we first subjected Ptpn2fl/fl Cd11cCre+/– mice and 
their WT littermate controls (Ptpn2fl/fl) to the AOM/DSS model and 
observed a significant reduction in tumor load and enhanced CD8+ T 
cell infiltration in Ptpn2fl/fl Cd11cCre+/– mice compared with their litter-
mates (Figure 7, A–C). Similar to Ptpn2fl/fl Cd4Cre+/– mice, we observed 
enhanced levels of effector/memory T cells in Ptpn2fl/fl Cd11cCre+/– 
mice (Figure 7C), suggesting that PTPN2-deficient DCs promote T 
cell activation. This finding is well in line with a recently published 
study from our group (24).
Next, we applied the orthotopic MC38 cecal injection model 
of CRC in Ptpn2fl/fl Cd11cCre+/– and Ptpn2fl/fl mice and found cellular 
and pathologic phenotypes similar to those observed in the AOM/
DSS model, which, again, mirrored the situation in the Ptpn2fl/fl 
Cd4Cre+/– tumor models. We found a considerably reduced tumor 
load (Figure 7D), changes in tumor morphology (Figure 7E), and 
significantly increased infiltration, activation, and cytotoxicity of 
CD8+ T cells (Figure 7, F–H). Thus, we hypothesize that in Ptpn2fl/fl 
Cd11cCre+/– mice, activated T cells, as in Ptpn2fl/fl Cd4Cre+/– mice, might 
mediate the reduction in tumor load.
PTPN2 deletion renders tumors more susceptible to anti–PD-1 
treatment. To investigate whether PTPN2 deletion makes T cells 
more susceptible to immunotherapy, we injected MC38 tumor cells 
s.c. into WT and Ptpn2fl/fl Cd4Cre+/– mice and administered anti–PD-1 
antibody on days 9, 12, and 15, when large (100–200 mm3) tumor 
nodules had formed (Figure 8A). Already in PTPN2-deficient mice 
receiving the IgG isotype control, we observed reduced tumor 
growth, but, strikingly, almost all Ptpn2fl/fl Cd4Cre+/– mice treated 
with anti–PD-1 cleared the tumors by day 20 (Figure 8, A and B). 
This additive effect on tumor reduction suggests that PTPN2 dele-
tion and anti–PD-1 therapy mediate tumor reduction through dis-
tinct mechanisms. In contrast, all WT mice reached the termination 
criteria because of tumor size, with or without anti–PD-1 treatment 
(Figure 8, A and B). Additionally, tumor morphology was altered in 
anti–PD-1–treated Ptpn2fl/fl Cd4Cre+/– mice, as evidenced by reduced 
cancer cell density and patches of immune cell infiltrates (Fig-
ure 8C). Anti–PD-1 treatment promoted CD8+ T cell infiltration in 
PTPN2-deficient mice, but not in WT mice (Figure 8D), indicating 
that PTPN2 depletion in T cells renders tumors more susceptible to 
checkpoint inhibitor treatment.
We further noted that the frequency of CD8+PD-1+ cells was 
significantly increased in IgG isotype–treated Ptpn2fl/fl Cd4Cre+/– 
mice when compared with frequencies in WT controls (Figure 8E). 
Depletion of PD-1 was successful in both WT and Ptpn2fl/fl Cd4Cre+/– 
mice and evident in CD8+ T cells, yet the anti–PD-1 therapy had 
much stronger effects on tumor load in the PTPN2-deficient mice. 
Last, checkpoint blockade did not change the activation or cyto-
toxicity of T cells in WT mice, whereas Ptpn2fl/fl Cd4Cre+/– mice had 
significantly higher frequencies of cytotoxic and activated T cells 
upon anti–PD-1 therapy (Figure 8E).
Increased immune memory formation in Ptpn2fl/fl Cd4Cre+/– mice. 
To determine whether PTPN2 deletion affects tumor-specific 
Figure 3. PTPN2 deletion in T cells promotes T cell activation in tumor tissue. 
Tumors were induced as described in Figure 2. (A) Representative images and 
quantification of CD4 IHC staining and flow cytometric analysis of WT and 
Ptpn2fl/fl Cd4Cre+/– untreated and tumor tissue. Flow cytometric analysis of 
untreated colon tissue, inflamed nontumor tissue, and inflamed tumor tissue 
(n = 5 mice in each group). Scale bars: 50 μm. P values were determined by 
1-way ANOVA with Tukey’s multiple-comparison test. (B and C) Frequencies 
of CD4+ T cells, effector/memory CD4+CD44+ T cells (spleen and mLNs), and 
Th1 cells (CD4+IFN-γ+), Th2 cells (CD4+IL-4+), Th17 cells (CD4+IL-17+), and Tregs 
(CD4+FoxP3+) (colon). P values were determined by 1-way ANOVA with Tukey’s 
multiple-comparison test. (D) Localization and quantification of CD8+ cells in 
Ptpn2fl/fl Cd4Cre+/– and WT untreated and tumor tissue. Scale bars: 50 μm. P 
values were determined by 1-way ANOVA with Tukey’s multiple-comparison 
test. (E) Frequencies of effector/memory CD8+CD44+ T cells (spleen and mLNs). 
P values were determined by 1-way ANOVA with Tukey’s multiple-comparison 
test. (F) Frequencies of CD8+granzyme B+, CD8+IFN-γ+, and the checkpoint 
molecule PD-1 on CD4+ and CD8+ T cells. P values were determined by 1-way 
ANOVA with Tukey’s multiple-comparison test. Data represent the mean ± SD. 
Freq., frequency.
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and that high PTPN2 gene expression correlated with reduced 
T cell activity, recruitment, and cytotoxicity. Using well-de-
fined mouse models, we verified that PTPN2 expression in T 
cells and DCs dampened antitumor immune responses and that 
PTPN2 deficiency led to significantly reduced tumor burden in 
vivo. Recent reports showed that PTPN2 silencing in T cells led 
to reduced tumor load in mice upon s.c. injection of MC38 and 
B16 cells and in mammary tumor mouse models (12, 13). While 
these studies showed altered T cell differentiation and enhanced 
antitumor response upon T cell–specific loss of PTPN2, they 
did not investigate human CRC tissues, nor did they examine 
whether cells of the in situ tumor microenvironment — which are 
critical for determining the therapeutic response — affect CRC 
tumor growth in vivo. In contrast, our study explored the poten-
tial of PTPN2 as a therapeutic target in different CRC models that 
adequately represent the tumor environment and development 
observed in patients with CRC.
Since in the majority of patients with CRC, low immunoge-
nicity of the tumors prevents response to immunotherapies (7, 
immune cell memory, we rechallenged Ptpn2fl/fl Cd4Cre+/– mice with 
a second injection of MC38 cells after they had cleared primary 
MC38 tumors following anti–PD-1 therapy. To compare primary 
and memory responses, we also injected MC38 cells into treat-
ment-naive Ptpn2fl/fl Cd4Cre+/– mice (Figure 8F). Mice that were 
rechallenged with MC38 cells developed smaller tumors than did 
mice that received primary injections, and all rechallenged mice, 
but only few mice that received primary injections, cleared the 
tumors (Figure 8F). Thus, PTPN2 deficiency not only promoted 
tumor clearance in synergy with anti–PD-1 treatment, but also 
induced memory responses that mediated spontaneous tumor 
clearance upon rechallenge.
Discussion
In this study, we demonstrate that immune cell–specific PTPN2 
plays an important role in the development of human CRC. Using 
a large collection of tissue samples from CRC with CRC, we show 
that PTPN2 protein expression and activity were highly elevated 
in human CRC tissue, with a marked increase in immune cells, 
Figure 4. Reduced tumor burden in orthotopic tumor injection and APCmin tumor models upon PTPN2 deletion in T cells. MC38 tumor cells (300,000 
cells) were injected into the cecal wall of WT and Ptpn2fl/fl Cd4Cre+/– mice. Mixed WT controls (Ptpn2fl/fl Cd4Cre– and Ptpn2fl/fl Cd11cCre–) were used in this exper-
iment, therefore, WT quantification in C is the same as the WT quantification in Figure 7F. (A) Representative gross image of cecal tumors from WT and 
Ptpn2fl/fl Cd4Cre+/– mice (n = 5 mice). (B) Total number of tumors and stratification according to size (n = 10 mice; n = 2 independent experiments) and tumor 
weight (n = 5 mice). P values were determined by 2-tailed Mann-Whitney U test. (C) Representative images and quantification of IHC staining and flow 
cytometric analysis of CD8 staining of Ptpn2fl/fl and Ptpn2fl/fl Cd4Cre+/– tumor tissue. Scale bars: 50 μm. P values were determined by 2-tailed Mann-Whitney 
U test. Frequencies of effector/memory CD8+CD44+ T cells in spleen (D) and of granzyme B, IFN-γ, and PD-1 in tumor (E). P values were determined by 
2-tailed Mann-Whitney U test. (F) Number of tumors in the small intestine and spleen weights for Ptpn2fl/fl APCmin and Ptpn2fl/fl Cd4Cre+/– APCmin mice.  
P values were determined by 2-tailed Mann-Whitney U test. Data represent the mean ± SD.
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PTPN2 is a known antiinflammatory protein that dephosphory-
lates several inflammatory mediators and prevents tissue inflamma-
tion (15–17, 21). PTPN2 deficiency in mice has previously been shown 
to affect pathologic immune responses as well as the development 
of T cells and B cells, to mediate hypersensitivity of macrophages, 
and to enhance the production of proinflammatory cytokines such 
8, 25, 26), therapeutic approaches that promote the immuno-
genic potential would result in improved treatment success. Our 
data from primary and metastatic human CRC tissues indicate a 
strong correlation between local PTPN2 expression and a reduced 
immune response. Thus, our observations in patients indicate that 
PTPN2 is an important target for CRC therapy.
Figure 5. CD8+ T cells are the key drivers of tumor reduction. MC38 tumor cells (300,000 cells) were injected s.c. into WT and Ptpn2fl/fl Cd4Cre+/– mice. 
(A) Representative image of MC38-induced tumors from WT and Ptpn2fl/fl Cd4Cre+/– mice. (B) MC38-induced tumor development (n = 5 WT mice and 10 
tumors; n = 4 Ptpn2fl/fl Cd4Cre+/– mice and 8 tumors) over time and tumor weights on the last day of the experiment. P values were determined by 2-tailed 
Mann-Whitney U test. (C) Scheme of CD8+ T cell depletion and image of representative tumors from IgG isotype control– and anti-CD8–treated WT and 
Ptpn2fl/fl Cd4Cre+/– mice. (D) Tumor sizes and weights (n = 6 WT IgG–treated mice and 12 tumors; n = 10 mice and 20 tumors for IgG-treated Ptpn2fl/fl Cd4Cre+/– 
mice, anti-CD8–treated WT mice, and anti-CD8–treated Ptpn2fl/fl Cd4Cre+/– mice; n = 2 independent experiments). P values were determined by 1-way ANO-
VA with Tukey’s multiple-comparison test. (E) Representative images and quantification of IHC and flow cytometric CD8 staining of WT and Ptpn2fl/fl  
Cd4Cre+/– mouse tumor tissue from IgG control– and anti–CD8–treated groups. Scale bars: 50 μm. P values were determined by 1-way ANOVA with Tukey’s 
multiple-comparison test. (F) Inverse correlation of tumor weight and frequency of CD8+ T cells in tumor tissue from WT and Ptpn2fl/fl Cd4Cre+/– mice. P and 
R2 values were determined by linear regression analysis. (G) Representative gross image of MC38 tumors from IgG isotype control– and anti-CD4–treated 
WT and Ptpn2fl/fl Cd4Cre+/– mice. (H) Tumor development (n = 5 mice and 10 tumors per group). P values were determined by 1-way ANOVA with Tukey’s 
multiple-comparison test. Data represent the mean ± SD.
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signaling resulted in increased mRNA expression of many chemo-
kines, but most significantly IFN-γ–inducible CXCL9 and CXCL11 
and their receptor CXCR3, within the tumor tissue, highlighting the 
enhanced potential to attract and accumulate cytotoxic T cells with-
in the tumor tissue. Hence, PTPN2 deficiency in T cells not only 
enhances activity and cytotoxicity of tumor-infiltrating T cells, but 
also facilitates their chemotaxis to the tumor.
PTPN2 deletion caused CD8+ T cells to be readily activated and 
enhanced their cytotoxicity and infiltration into tumor sites. In con-
currence with the inverse correlation between PTPN2 and PD-1 in 
human CRC, we demonstrated that absence of PTPN2 in T cells pro-
moted the efficacy of anti–PD-1 therapy in murine CRC, resulting in 
complete tumor clearance. In line with an increased and sustained 
anti–PD-1 response, gene expression profiling revealed increased 
mRNA expression of Cxcr3 and Cxcr5 — chemokine receptors cru-
cial for efficient anti–PD-1 responses(30, 33) and memory forma-
tion (34, 35), respectively. Of importance for potential therapeutic 
strategies targeting PTPN2 in T cells is the memory formation that 
mediated the complete clearance of secondary tumors in mice lack-
ing PTPN2 in T cells, indicating that PTPN2 deletion or inhibition 
might not only serve as a potential treatment in primary CRC, but 
might also significantly extend relapse-free survival.
Our data indicate that targeting PTPN2 represents a high-
ly promising approach to enhance T cell tumor infiltration and 
tumor-specific cytotoxic activity and improve treatment response 
in tumors that are refractory to checkpoint inhibitors because of 
low immunogenicity. Additionally, our data suggest that target-
ing PTPN2 may prolong tumor-free survival via development of 
immune memory formation.
as IFN-γ, TNF, and IL-1β (18, 19, 21). We previously showed that con-
ditional PTPN2 KO (cKO) in T cells promotes Th1 and Th17 differen-
tiation and results in increased IFN-γ and IL-17 production in colitis 
models (17). Furthermore, T cell cKO has been shown to promote T 
cell activation and promote TCR-dependent CD8+ T cell prolifera-
tion (14). Additionally, we recently demonstrated that cKO in DCs 
promotes Th1 differentiation and IFN-γ production via upregulation 
of costimulatory molecules in PTPN2-deficient DCs (24).
Here, we demonstrate again that PTPN2 deletion in T cells 
and DCs increased IFN-γ production, which promoted the dif-
ferentiation and activation of CD4+ Th1 cells and increased the 
cytotoxic ability of CD8+ T cells. Of key importance to the ther-
apeutic potential to inhibit PTPN2 function, however, is the fact 
that the highly increased frequency of granzyme B–producing, 
PTPN2-deficient CD8+ T cells was mainly confined to the tumor 
tissues, whereas levels in healthy tissues from tumor-bearing mice 
were only slightly increased compared with levels in WT controls. 
This suggests that specific antigen stimulation is necessary for 
the boosted CD8+ T cell response and that T cell–specific PTPN2 
depletion or inhibition would probably not affect nontumor tis-
sues. This unveils a therapeutic rationale for the use of T cell–spe-
cific PTPN2 inhibitors as an adjuvant therapy in CRC.
In agreement with the tumor-specific CD8+ T cell activation 
in the absence of PTPN2 in T cells or DCs, we observed highly 
increased intratumoral infiltration of PTPN2-deficient CD8+ T cells. 
IFN-γ–inducible chemokines, specifically CXCL9, CXCL10, and 
CXCL11 and their receptor CXCR3, have been described as import-
ant modulators of CD8+ T cell recruitment to tumor tissue (27–32). 
Here, we found that PTPN2 deletion in T cells and enhanced IFN-γ 
Figure 6. Tumor reduction after therapeutic PTPN2-deficient CD8+ T cell transfer. (A) Scheme of WT or Ptpn2fl/fl Cd4Cre+/– CD8+ T cell transfer into Rag2–/– 
mice. (B) Representative image, development curve, and weights of MC38 tumors from mice without T cell transfer (n = 6 mice and 12 tumors), or with 
either WT CD8+ T cell (n = 5 mice and 10 tumors) or Ptpn2fl/fl Cd4Cre+/– CD8+ (n = 6 mice/ 12 tumors) T cell transfer. P values were determined by 2-tailed 
Mann-Whitney U test. (C) In vitro killing assay of MC38 and MC38-OVA cells by WT and Ptpn2fl/fl Cd4Cre+/– OT-I T cells. Graphs represent early (annexin 
V+zombieNIR–) and late (annexin V+zombieNIR+) apoptotic cells. P values were determined by 1-way ANOVA with Tukey’s multiple-comparison test. Data 
represent the mean ± SD. W/O, without addition of T cells.
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Figure 7. PTPN2 deletion in DCs leads to reduced tumor load in the AOM/DSS and orthotopic injection models. Tumor development was induced in WT 
mice (n = 5 mice) and their Ptpn2fl/fl Cd11cCre+/– littermates (ΔDC) (n = 5 mice) using the AOM/DSS model and the cecal injection model. Mixed WT controls 
(Ptpn2fl/fl Cd4Cre– and Ptpn2fl/fl Cd11cCre–) were used in these experiments, thus, WT quantification in F is the same as the WT quantification in Figure 4C. 
(A) Representative colonoscopy images. (B) Quantification of the total tumor numbers and according to tumor size. P values were determined by 2-tailed 
Mann-Whitney U test. Flow cytometry analysis was performed on healthy colon, inflamed nontumor, and inflamed tumor tissue. (C) Frequencies of CD8+ 
T cells (colon) and effector/memory CD8+CD44+ T cells (spleen). P values were determined by 2-tailed Mann-Whitney U test. (D) Gross images of ceca 
and plot of tumor weights for WT and Ptpn2fl/fl Cd11cCre+/– littermate mice. P value was determined by 2-tailed Mann-Whitney U test. (E) H&E staining of 
tumor tissue from WT and Ptpn2fl/fl Cd11cCre+/– mice. Scale bars: 100 μm. (F) Representative images and analysis of IHC and flow cytometric frequency of 
CD8 staining in WT and Ptpn2fl/fl Cd11cCre+/– mouse tumor tissue. Scale bars: 50 μm. P values were determined by 2-tailed Mann-Whitney U test. (G and 
H) Frequencies of effector/memory CD8+CD44+ T cells (spleen) and the cytotoxicity markers granzyme B, perforin, IFN-γ, and TNF (tumor). P values were 
determined by 2-tailed Mann-Whitney U test. Data represent the mean ± SD.
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the phosphatase activity assay and paraffin-embedded primary colon 
tumor, liver, and lung metastasis tissue slides for PTPN2, PD-1, and 
CTLA4 IHC stainings were obtained from the Pathology Department 
of the University Hospital Zurich (Zurich, Switzerland). The tissue 
microarray slides containing melanoma tissue for PTPN2 and PD1 
staining were obtained from the Department of Dermatology of the 
University Hospital Zurich.
Methods
Human samples. Paraffin-embedded human tissue slides used for 
PTPN2 and p-STAT1 were obtained from the Translational Research 
Center in Erlangen, Germany. RNA analysis was performed by the 
Translational Research Center in Erlangen, Germany, as described 
previously (36). A list of primers and probes can be found in Supple-
mental Table 1. Cryopreserved nontumor and colon tumor tissues for 
Figure 8. PTPN2 deficiency and anti–PD-1 therapy lead to an enhanced synergetic antitumor response. (A) Schematic overview of the treatment and 
representative gross images of tumors from WT and Ptpn2fl/fl Cd4Cre+/– mice treated with IgG control or anti–PD-1 antibody. (B) Tumor development and 
weights (n = 10 mice and 20 tumors; n = 2 independent experiments). P values were determined by 1-way ANOVA with Tukey’s multiple-comparison test. 
(C) H&E staining of tumor tissue from WT and Ptpn2fl/fl Cd4Cre+/– mice. Scale bars: 100 μm. (D) Representative images of IHC staining and flow cytometric 
frequency of CD8 staining of WT and Ptpn2fl/fl Cd4Cre+/– mice tumor tissue. Scale bars: 100 μm. 1-way ANOVA with Tukey’s multiple-comparison test. (E) Fre-
quencies of PD-1, CD44, granzyme B, and perforin on CD8+ T cells from IgG control and anti–PD-1 groups. P values were determined by 1-way ANOVA with 
Tukey’s multiple-comparison test. (F) Outline of the primary and memory response experiment and tumor development curve for Ptpn2fl/fl Cd4Cre+/– mice 
(first primary response, n = 7 mice and 14 tumors; memory n = 7 mice and 9 tumors; second primary response n = 13 mice and 13 tumors; n = 2 independent 
experiments). P values were determined by 1-way ANOVA with Tukey’s multiple-comparison test. Data represent the mean ± SD.
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(Bio X Cell; clone LTF-2). Antibodies were injected i.p. at a concentra-
tion of 200 mg/mouse on day –3, day 0, and every 3 days thereafter. 
PD-1 blockade was performed in the s.c. tumor model and achieved 
by i.p. injection of 200 mg/mouse anti–PD-1 (CD279) antibody (Bio X 
Cell; clone 29F.1A12) or IgG isotype control (Bio X Cell; clone 2a3) on 
days 9, 12, and 15 after injection of MC38 cells.
For adoptive transfer, 500,000 CD8+ T cells from Ptpn2fl/fl and 
Ptpn2fl/fl Cd4Cre+/– mice were transferred by i.p. injection into Rag2–/– 
mice on day 6 after the s.c. MC38 tumor injection.
Histology. Tumor and tumor-adjacent tissue from patients, the 
most distal colon sections from the AOM/DSS experiment mice, and 
tumors from s.c. injection experiments were used for H&E staining, 
IHC, and immunofluorescence (IF).
Tissues for IF were deparaffinized and antigens retrieved using 
citrate buffer, pH 6.0 (Dako), at 98°C for 30 minutes. Slides were 
maintained in PBS with 10% goat serum, 10% BSA, and 0.3% Triton 
X (MilliporeSigma) for 1 hour at room temperature (RT) to block the 
nonspecific binding. Primary antibodies for IF were diluted in 1% 
BSA, 1% goat serum, and 0.3% Triton X and incubated overnight at 
4°C. A list of antibodies is provided in Supplemental Table 2. Slides 
were washed with 3% milk and PBS solution. Secondary goat anti–
rabbit AF647 (Thermo Fisher Scientific) and goat anti–mouse AF594 
(Thermo Fisher Scientific) were diluted in 1% BSA, 1% goat serum, 
and 0.3% Triton X, and the slides were incubated for 1 hour, washed 
with PBS, and then mounted. Fluorescence-labeled tissue sections 
were examined using the Leica SP8 Upright microscope and Leica LAS 
X and LAS AF Lite software.
H&E staining was performed according to standard procedures. 
Tissues for IHC were deparaffinized and antigens retrieved using 
citrate buffer, pH 6.0 (Dako), at 98°C for 30 minutes. Inhibition of 
endogenous peroxidases was performed by incubation of tissue slides 
in 0.9% hydrogen peroxide for 15 minutes at RT. Horse serum (2.5%) 
for blockage of nonspecific binding was used for p-STAT1 and CD4 
staining for 1 hour and for PTPN2 in human tissue for 2 hours at RT. 
For CD3, CD8, PD-1, and CTLA4 staining, 3% BSA blocking solu-
tion was used for 1 hour. Primary antibodies were diluted in blocking 
solutions and slides incubated overnight at 4°C. A list of antibodies is 
provided in Supplemental Table 2. A secondary HRP-labeled antibody 
(Vector Laboratories, ImmPRESS) was applied for IHC samples for 1 
hour at RT, and staining was visualized using the DAB ImmPACT Per-
oxidase Substrate Brown Kit (Vector Laboratories). IHC samples were 
counterstained with hematoxylin, dehydrated, and mounted. Tissue 
sections were examined using the Zeiss Axio Imager Z2 and Zeiss 2.6 
(Blue Edition) software.
qPCR. Healthy and tumor tissues (0.5 cm) were homogenized 
using gentleMACS (Miltenyi Biotec), and RNA was isolated using 
the Maxwell RSC simplyRNA Tissue Kit (Promega) according to 
the manufacturer’s instructions. RNA concentration was measured 
using absorbance at 260 and 280 nm. cDNA was synthesized using 
the high-capacity cDNA Reverse Transcription Kit (Thermo Fisher 
Scientific) according to the manufacturer’s instructions. qPCR was 
performed using FAST qPCR Master Mix and predesigned TaqMan 
assays (Thermo Fisher Scientific) on a QuantStudio 6 system using 
QuantStudio software (Thermo Fisher Scientific). Mouse GAPDH 
was used as an endogenous control. Relative expression levels were 
calculated according to the ΔΔCt method, and samples were mea-
sured in triplicate.
Phosphatase activity assay. Samples for phosphatase activity mea-
surements were homogenized using the genteMACS tissue homoge-
nizer (Miltenyi Biotec), and proteins were per-cleared using sephar-
ose G beads (GE Healthcare) and then incubated overnight (o/n) 
at 4°C on a rocker with 10 μg/mL rabbit anti-PTPN2 (Calbiochem; 
clone CF4-1D). Beads were added after o/n incubation and left on 
the rocker for 1 hour at 4°C. Precipitates were washed with PBS and 
phosphatase activity measured using the EnzChek Kit (Thermo Fish-
er Scientific). Fluorescence units (FU) were measured every 10 min-
utes on a Synergy HT plate reader using Gen5 software (both from 
BioTek Instruments).
Mice. C57BL/6N mice carrying Cre under the Cd4 promoter were 
purchased from Taconic, CD11cCre-GFP line 4097 mice from The 
Jackson Laboratory, Ptpn2fl/fl mice from EUCOMM (Germany), APC­
min mice from The Jackson Laboratory, Rag2–/– mice from Charles 
River Laboratories, and OT1/J mice from The Jackson Laboratory. 
All mice were kept in specific pathogen–free conditions. Ptpn2fl/fl mice 
were bred with Cd4Cre mice to obtain specific PTPN2 deletion in T cells 
(17) and with Cd11cCre–GFP mice to create specific deletion of PTPN2 
in DCs. Mice heterozygous for Cd4Cre (Ptpn2fl/fl Cd4Cre+/–) or Cd11cCre 
(Ptpn2fl/fl Cd11Cre+/–) were bred with Ptpn2fl/fl (WT) mice to obtain Cre+/– 
and Cre–/– littermate controls (Ptpn2fl/fl Cd4Cre– Ptpn2fl/fl CD4Cre+/– and 
Ptpn2fl/fl Cd11cCre– Ptpn2fl/fl Cd11cCre+/–, respectively). Males and females 
between 8–12 weeks of age were used for all experiments, except for 
AOM/DSS tumor induction, for which only females were used. Litter-
mate controls were used for all experiments. Mixed Ptpn2fl/fl Cd4Cre– and 
Ptpn2fl/fl Cd11cCre– control mice (referred to as Ptpn2fl/fl  or WT controls) 
were used for AOM/DSS and cecal injection tumor models to minimize 
the number of animals required. Whenever mixed control animals 
were used, both Ptpn2fl/fl Cd4Cre+/– and Ptpn2fl/fl Cd11Cre+/– groups were 
included in the same experiment and run in parallel. Experiments with 
mixed control groups are indicated in the figure legends.
Tumor models and treatments. Colitis-associated tumors were 
induced as described previously (19) by administering DSS (MP Bio-
medicals) in the drinking water and injecting AOM (MilliporeSigma; 
10 mg/kg in saline). Control mice received water and were injected 
with saline. Mice were euthanized 10 days after the last DSS treat-
ment. After the third DSS cycle and at the end of the experiment, mice 
were anesthetized by i.p. injection of ketamine (90–120 mg/kg body 
weight; Vetoquinol) and xylazine (8 mg/kg body weight; Bayer), and a 
colonoscopy was performed to monitor tumor growth.
For injection models, MC38-GFP (donated by Lubor Borsig, 
Institute of Physiology, University of Zurich, Zurich, Switzerland) 
or B16-F10 tumor cells were suspended in culture medium, mixed 
1:1 with Matrigel and 300,000 cells, and injected into the cecal wall 
or s.c. into the mouse flank. Mice were euthanized 2–3 weeks after 
injection. In the s.c. model, tumor development was measured every 
3 days using a digital caliper. Tumor volume was calculated using 
the ellipsoid formula: 4/3 × 3.14 × length/2 × (width/2)2, where the 
shorter dimension was used as the width and depth. Mice were euth-
anized when the volume reached 1 cm3 or the length reached 2 cm.
CD8+ T cells depletion was performed using anti-CD8 (Lyt 3.2) 
antibody (Bio X Cell; clone 53-5.8) or IgG isotype control (Bio X Cell; 
clone HRPN). Antibodies were injected i.p. in a concentration of 200 
mg/mouse on day –3 and 100 mg/mouse on day 0 and then once 
weekly thereafter. CD4+ T cells depletion was performed using an 
anti-CD4 antibody (Bio X Cell; clone GK 1.5) or an IgG isotype control 
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Flow cytometric analysis. Spleen, mesenteric and skin draining 
LNs, colon lamina propria lymphocytes (LPLs), and tumor cells were 
used for flow cytometric analysis. Single-cell suspensions from spleen, 
LNs, and LPLs were prepared as described previously (37). Cecal and 
s.c. tumors were cut into pieces of approximately 0.5 mm3 in size and 
digested in 6 mL containing 0.5 mg/mL collagenase type IV (Milli-
poreSigma) and 0.05 mg/mL DNAse I (Roche) solution for 10 minutes 
on a shaker (300 rpm) at 37°C. Cells were homogenized by passage 
through an 18 gauge × 1.5 inch syringe and centrifuged for 10 minutes 
at 4°C and 300g. Single-cell suspensions were stained and restimulated 
as described previously (38). The antibodies used are listed in Supple-
mental Table 3.
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sequencing were performed by Microsynth.
Transcripts were quantified with kallisto 0.44.0 (39) using the 
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fication of less than 10 were discarded from the downstream analysis. 
Differential expression analysis was performed in R (40) with DESeq2 
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sue:genotype. Shrinkage of log
2
 fold changes was estimated using 
apeglm (42). All sequencing data can be found in the ArrayExpress 
database (accession number E-MTAB-9629).
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incubated for 24 hours at 37°C. Cells were then kept alone or cocul-
tured with enriched CD8+ T cells from spleens of either Ptpn2fl/fl Cd4Cre– 
OT I or Ptpn2fl/fl Cd4Cre+/– OT I mice for 24 hours in a 37°C incubator. 
CD8+ T cells were enriched using the EasySep CD8+ T Cell Enrich-
ment Kit (STEMCELL Technologies). Apoptosis was then detected 
using the Annexin V Kit – DY-634 Antibody (Abcam) and the Zombie 
NIR Fixable Viability Kit (BioLegend).
Statistics. For 2-group comparisons, a nonparametric, 2-tailed 
Mann-Whitney U test was performed, and for comparison of 3 or more 
groups, a 1-way ANOVA followed by Tukey’s multiple-comparison test 
was used. All experiments, which were performed in parallel, were 
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